Globus Medical (NYSE:GMED – Free Report) had its target price reduced by Canaccord Genuity Group from $115.00 to $105.00 in a report published on Friday morning,Benzinga reports. They currently have a buy rating on the medical device company’s stock.
Several other analysts have also recently commented on the stock. Royal Bank Of Canada reduced their price objective on shares of Globus Medical from $115.00 to $85.00 and set an “outperform” rating for the company in a research note on Thursday, October 1st. BMO Capital Markets lowered shares of Globus Medical from an “outperform” rating to a “market perform” rating and lowered their target price for the stock from $94.00 to $78.00 in a research report on Friday. Weiss Ratings reaffirmed a “hold (c+)” rating on shares of Globus Medical in a report on Friday, October 9th. Zacks Research raised shares of Globus Medical from a “hold” rating to a “strong-buy” rating in a report on Monday, August 10th. Finally, BTIG Research reissued a “neutral” rating on shares of Globus Medical in a research note on Friday. Two equities research analysts have rated the stock with a Strong Buy rating, eight have issued a Buy rating and six have assigned a Hold rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $96.92.
Check Out Our Latest Research Report on Globus Medical
Globus Medical Stock Performance
NYSE:GMED traded down $10.77 during trading hours on Friday, hitting $70.67. The company’s stock had a trading volume of 9,272,194 shares, compared to its average volume of 1,321,886. The business’s 50-day moving average is $77.20 and its two-hundred day moving average is $83.18. The company has a market capitalization of $9.49 billion, a PE ratio of 17.36, a PEG ratio of 1.28 and a beta of 0.98. Globus Medical has a 52-week low of $70.39 and a 52-week high of $101.40.
Globus Medical (NYSE:GMED – Get Free Report) last released its earnings results on Thursday, November 5th. The medical device company reported $1.23 EPS for the quarter, beating analysts’ consensus estimates of $1.20 by $0.03. The company had revenue of $763.72 million during the quarter, compared to the consensus estimate of $792.39 million. Globus Medical had a return on equity of 14.57% and a net margin of 17.02%. Globus Medical’s quarterly revenue was down .7% compared to the same quarter last year. During the same quarter last year, the company earned $1.18 earnings per share. Globus Medical has set its FY 2026 guidance at 4.950-5.050 EPS. As a group, analysts predict that Globus Medical will post 4.99 EPS for the current fiscal year.
Insider Activity
In other news, Director Stephen Zarrilli sold 25,000 shares of the firm’s stock in a transaction that occurred on Tuesday, August 18th. The shares were sold at an average price of $87.04, for a total transaction of $2,176,000.00. Following the completion of the transaction, the director directly owned 25,000 shares of the company’s stock, valued at $2,176,000. This trade represents a 50.00% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Ann Rhoads sold 5,000 shares of Globus Medical stock in a transaction that occurred on Wednesday, November 4th. The stock was sold at an average price of $85.00, for a total value of $425,000.00. Following the transaction, the director owned 35,384 shares of the company’s stock, valued at $3,007,640. This represents a 12.38% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 60,000 shares of company stock worth $4,838,400 over the last ninety days. 18.38% of the stock is currently owned by insiders.
Hedge Funds Weigh In On Globus Medical
A number of institutional investors have recently made changes to their positions in the stock. Janus Henderson Group PLC lifted its position in shares of Globus Medical by 4.5% in the first quarter. Janus Henderson Group PLC now owns 7,623,095 shares of the medical device company’s stock valued at $656,831,000 after acquiring an additional 328,217 shares in the last quarter. Sculptor Capital LP increased its position in Globus Medical by 1.9% during the 1st quarter. Sculptor Capital LP now owns 3,058,000 shares of the medical device company’s stock worth $263,477,000 after purchasing an additional 58,000 shares in the last quarter. Dimensional Fund Advisors LP increased its position in Globus Medical by 2.0% during the 1st quarter. Dimensional Fund Advisors LP now owns 1,769,897 shares of the medical device company’s stock worth $152,474,000 after purchasing an additional 33,976 shares in the last quarter. Allspring Global Investments Holdings LLC raised its stake in Globus Medical by 14.3% in the 3rd quarter. Allspring Global Investments Holdings LLC now owns 1,797,215 shares of the medical device company’s stock valued at $133,731,000 after purchasing an additional 225,534 shares during the last quarter. Finally, Boston Trust Walden Corp raised its stake in Globus Medical by 4.4% in the 3rd quarter. Boston Trust Walden Corp now owns 1,643,143 shares of the medical device company’s stock valued at $123,071,000 after purchasing an additional 69,782 shares during the last quarter. 95.16% of the stock is owned by institutional investors and hedge funds.
More Globus Medical News
Here are the key news stories impacting Globus Medical this week:
- Positive Sentiment: Third-quarter adjusted earnings were $1.23 per share, ahead of the $1.20 consensus and up from $1.18 a year earlier. Globus also increased its share-repurchase authorization by $500 million, offering potential support for shareholder returns. Third-quarter results and repurchase announcement
- Neutral Sentiment: Analyst views were mixed: Canaccord and Needham cut their price targets but maintained Buy ratings, while Wells Fargo slightly raised its target and kept an Overweight rating. The company is also seeking acquisitions, though the provided report does not detail potential deals. Report on acquisition plans
- Negative Sentiment: Revenue of $763.7 million missed the $792.4 million analyst estimate and declined 0.7% year over year. Full-year 2026 revenue guidance of $3.1 billion is below the roughly $3.2 billion consensus; management cited spine-product launch delays and weak Nevro sales, weighing on expectations despite EPS guidance being broadly in line. Q3 call highlights and outlook
- Negative Sentiment: BMO Capital Markets downgraded GMED from Outperform to Market Perform and cut its price target, adding to concerns about the outlook. Coverage of the stock decline
Globus Medical Company Profile
Globus Medical, Inc develops and commercializes musculoskeletal solutions for surgeons, hospitals and patients. The company focuses primarily on spinal, orthopedic trauma and other orthopedic procedures, offering implants, instruments and related technologies designed to support surgical treatment and improve clinical outcomes.
Its product portfolio includes spinal implants and enabling technologies, including the ExcelsiusGPS robotic navigation platform and Excelsius3D imaging system.
Read More
- Five stocks we like better than Globus Medical
- Dutch Bros Gave Wall Street What It Wanted, So Why Did the Stock Crater?
- Astera Labs Just Crushed Earnings—So Why Are Analysts Cutting Price Targets?
- Sandisk Shares Are Oversold: Bargain or Value Trap?
- IonQ’s Record Revenue Includes a Big SkyWater Boost: Does That Change the Story?
Receive News & Ratings for Globus Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Globus Medical and related companies with MarketBeat.com's FREE daily email newsletter.
